<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font28 { font-size : 28; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">patients </span>
   <span class="font28">HCC </span>
   <span class="font20">development </span>
   <span class="font19">SVR </span>
   <span class="font18">treatment </span>
   <span class="font17">hepatitis </span>
   <span class="font16">.%, </span>
   <span class="font16">antiviral </span>
   <span class="font15">HCV </span>
   <span class="font15">CHC </span>
   <span class="font15">PEG-IFN/RBV </span>
   <span class="font15">chronic </span>
   <span class="font15">study </span>
   <span class="font14">rates </span>
   <span class="font14">risk </span>
   <span class="font14">therapy </span>
   <span class="font14">hepatocellular </span>
   <span class="font14">{border-style </span>
   <span class="font14">cumulative </span>
   <span class="font14">genotype </span>
   <span class="font14">no-treatment </span>
   <span class="font14">plus </span>
   <span class="font13">new </span>
   <span class="font13">px;} </span>
   <span class="font13">significantly </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">(HR </span>
   <span class="font13">ribavirin </span>
   <span class="font13">treated </span>
   <span class="font13">greater </span>
   <span class="font13">factors </span>
   <span class="font13">group </span>
   <span class="font13">group, </span>
   <span class="font13">(−) </span>
   <span class="font13">age </span>
   <span class="font13">cirrhosis </span>
   <span class="font13">liver </span>
   <span class="font13">rate </span>
   <span class="font12">(.%) </span>
   <span class="font12">carcinoma </span>
   <span class="font12">older </span>
   <span class="font12">DAA </span>
   <span class="font12">presence </span>
   <span class="font12">present </span>
   <span class="font12">(Fig. </span>
   <span class="font12">P &amp;lt; .), </span>
   <span class="font12">higher </span>
   <span class="font12">Hepatol;:–. </span>
   <span class="font12">achieve </span>
   <span class="font12">follow-up </span>
   <span class="font12">study, </span>
   <span class="font12">sustained </span>
   <span class="font11">-year </span>
   <span class="font11">active </span>
   <span class="font11">based </span>
   <span class="font11">cirrhosis, </span>
   <span class="font11">respectively, </span>
   <span class="font11">(.%, </span>
   <span class="font11">(Table </span>
   <span class="font11">P &amp;lt; .) </span>
   <span class="font11">Study </span>
   <span class="font11">advanced </span>
   <span class="font11">age, </span>
   <span class="font11">developed </span>
   <span class="font11">px; </span>
   <span class="font11">response </span>
   <span class="font11">study. </span>
   <span class="font11">subjects </span>
   <span class="font11">virologic </span>
   <span class="font11">virus </span>
   <span class="font11">{font-family </span>
   <span class="font11">agents </span>
   <span class="font11">analysis </span>
   <span class="font11">characteristics </span>
   <span class="font11">did </span>
   <span class="font11">drugs </span>
   <span class="font11">effective </span>
   <span class="font11">font-size </span>
   <span class="font11">genotypes </span>
   <span class="font11">infection </span>
   <span class="font11">infection. </span>
   <span class="font11">median </span>
   <span class="font11">patients, </span>
   <span class="font11">previous </span>
   <span class="font11">(P &amp;lt; .) </span>
   <span class="font11">(n = ) </span>
   <span class="font11">Hepatology;:–. </span>
   <span class="font11">RNA </span>
   <span class="font11">Table </span>
   <span class="font11">as, </span>
   <span class="font11">associated </span>
   <span class="font11">cirrhosis. </span>
   <span class="font11">cirrhotic </span>
   <span class="font11">clinical </span>
   <span class="font11">development. </span>
   <span class="font11">double; </span>
   <span class="font11">effects </span>
   <span class="font11">enrolled </span>
   <span class="font11">high </span>
   <span class="font11">highly </span>
   <span class="font11">interferon </span>
   <span class="font11">oral </span>
   <span class="font11">patients. </span>
   <span class="font11">reported </span>
   <span class="font11">using </span>
   <span class="font11">(P = .) </span>
   <span class="font11">HCV-related </span>
   <span class="font11">However, </span>
   <span class="font11">anti-HCV </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">considered </span>
   <span class="font11">data </span>
   <span class="font11">era </span>
   <span class="font11">evidence </span>
   <span class="font11">failed </span>
   <span class="font11">incidence </span>
   <span class="font11">independent </span>
   <span class="font11">independently </span>
   <span class="font11">peg-interferon </span>
   <span class="font11">predictive </span>
   <span class="font11">recurrence </span>
   <span class="font11">retrospective </span>
   <span class="font11">serum </span>
   <span class="font11">solid; </span>
   <span class="font11">studies </span>
   <span class="font11">therapy. </span>
   <span class="font11">treatment. </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">Figure </span>
   <span class="font10">Inha </span>
   <span class="font10">Liver </span>
   <span class="font10">Med;:–. </span>
   <span class="font10">Median </span>
   <span class="font10">University </span>
   <span class="font10">al.Efficacy </span>
   <span class="font10">allocated </span>
   <span class="font10">bold </span>
   <span class="font10">candidates </span>
   <span class="font10">carcinoma, </span>
   <span class="font10">carcinoma: </span>
   <span class="font10">courier; </span>
   <span class="font10">diagnosis </span>
   <span class="font10">direct-acting </span>
   <span class="font10">duration </span>
   <span class="font10">em; </span>
   <span class="font10">factor </span>
   <span class="font10">long-term </span>
   <span class="font10">lower </span>
   <span class="font10">male </span>
   <span class="font10">months </span>
   <span class="font10">months. </span>
   <span class="font10">needs </span>
   <span class="font10">patient </span>
   <span class="font10">peginterferon </span>
   <span class="font10">predicted </span>
   <span class="font10">pt;} </span>
   <span class="font10">regimens </span>
   <span class="font10">sofosbuvir </span>
   <span class="font10">subgroups </span>
   <span class="font10">subjects, </span>
   <span class="font10">treatment-naïve </span>
   <span class="font10">weeks </span>
  </p>
 </body>
</html>
